Oral Presentation: Comprehensive Cancer Care ll: Integrating
Complementary & Alternative Therapies,
Sponsored by Center for Mind-Body Medicine & National Cancer Institute, at the Hyatt Regency in Crystal City, Arlington, VA, June 1999.
A PILOT SURVEY: STANDARD CANCER THERAPY COMBINED WITH NUTRACEUTICAL DIETARY
SUPPLEMENTATION IMPROVES TREATMENT RESPONSES AND PATIENT QUALITY OF LIFE. G.
Hyland, M.D., D. Miller, M.T., Medcenter One, Dept. Radiation Oncology,
Bismarck, North Dakota.
In thousands of cancer cases evaluated by H. Foster, 87% percent of those with
"spontaneous remissions" had made major dietary changes prior to tumor
regression. The Dietary Supplement Health Education Act of 1994 resulted in
millions of US citizens adding a plethora of supplements to their diets. A
favorable response by 5 patients that failed all cancer therapy was noted after
it was stopped. We found that they had consumed glyconutrient, phytonutrient and
phytogenin containing dietary supplements.
A search revealed that Dr. Busbee et. al 1994 found a glyconutrient in these
diet supplements increased IL-1, IL-6, INF and TNF production in monocyte
cultures. Dr. See et. al 1999 reported enhanced NK lymphocyte cytolytic function
in response to multiple glyconutrients. Dr. Barhomi et. al 1997 found
glyconutrients increased intracellular reduced-glutathione protection 50% in
liver cells. Such activity provides a potential differential effect for tumor
cell destruction and normal cell protection.
To increase our observations, patients with malignancies were solicited from a 3
state area and 127 volunteered to add nutraceuticals to their diet. 100 patients
returned a quality of life survey focusing on weight loss, fatigue, nausea,
vomiting, pain control, ability to complete treatments on schedule, physical
activity and sense of well being. 40% of the group had failed standard therapy
and were in a state of progressive disease (sent home to die). 60% were starting
radiation or chemo-therapy. 85% reported improvements in the above clinical
parameters.
The phytogenin supplement contains plant sterols for nutrient based endocrine
support. Ovarian, breast, uterine, and prostate malignancy patients were
discouraged from taking this nutrient. Some elected to add the phytogenin to
their diet and they reported the best preservation of appetite, muscle mass, and
had the least side-effects during treatment. Patients with a diagnoses of
ovarian carcinoma, astrocytoma grade IV, lymphoma with mild marrow suppression,
a massive pelvic myxosarcoma, and colon adenocarcinoma with brain metastasis had
unprecedented responses.
CONCLUSIONS: Nutraceutical dietary supplements:
1. Do not inhibit tumor cell destruction by radiation and chemotherapy
2. Enhance tumor cell destruction
3. Protect normal cells from radiation and cytotoxic damage
4. Induce reductions in tumor mass in malignancies resistant to all treatments
5. Improve quality of life for patients by reducing treatment toxicity and side
effects from radiation and chemotherapy. A formal, controlled clinical study is
warranted to further evaluate the effects of nutraceutical dietary
supplementation in combination with standard cancer therapy.